View Publication On PubMed
Export African trypanosomes are the causative agents of neglected tropical diseases affecting both humans and livestock. Disease control is highly challenging due to an increasing number of drug treatment failures. African trypanosomes are extracellular, blood-borne parasites that mainly rely on glycolysis for their energy metabolism within the mammalian host. Trypanosomal glycolytic enzymes are therefore of interest for the development of trypanocidal drugs. Here, we report the serendipitous discovery of a camelid single-domain antibody (sdAb aka Nanobody) that selectively inhibits the enzymatic activity of trypanosomatid (but not host) pyruvate kinases through an allosteric mechanism. By combining enzyme kinetics, biophysics, structural biology, and transgenic parasite survival assays, we provide a proof-of-principle that the sdAb-mediated enzyme inhibition negatively impacts parasite fitness and growth.
SEEK ID: https://fairdomhub.org/publications/788
PubMed ID: 40163365
Projects: WG1 - Compound libraries coordination and integration of compound design, WG2 - Integration of early phase studies and low environmental impact ac..., WG3 - Coordination of in vitro-to-in vivo translation of OneHealth leads..., WG4 - Integration of R&D process-environmental studies and translation i...
Publication type: Journal Article
Journal: Elife
Citation: Elife. 2025 Mar 31;13:RP100066. doi: 10.7554/eLife.100066.
Date Published: 31st Mar 2025
Registered Mode: by PubMed ID
SubmitterViews: 8
Created: 14th Jul 2026 at 08:25
TagsThis item has not yet been tagged.
AttributionsNone
Download
https://orcid.org/0000-0002-4870-3202